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summary
The WNT signalling pathway is a complex system for transferring information for DNA expression from the 
cell surface receptors to cytoplasm and then to the nucleus. It is based on several proteins that work together as 
agonists and antagonists in order to maintain homeostasys and to promote anabolic processes.
The WNT system acts on all cellular lines involved in bone resorption and formation. WNT pathway can mainly 
be triggered by two different signalling cascades. The first is well known and is the so-called WNT-beta catenin 
system (or the canonical pathway), the second is known as the non canonical WNT pathway.
WNT proteins form a superfamily of secreted glycoproteins. The association with surface receptors, called 
Frizzled, that are members of the G protein-coupled receptors superfamily and co receptors like low-density 
lipoprotein receptor-related proteins 5 and 6 (LRP5/6) complete the WNT system. LRP5/6 show high affinity 
for WNT antagonists that modulate the activity of this pathway: DKK1 and sclerostin (SCL), that play a cru-
cial role in modulating the WNT system. The WNT-pathway and in particular its antagonists SCL and DKK1 
seems to play a key role in the regulation of bone remodeling during treatment with bone active agents such as 
bisphosphonates, but not only. Their effects become relevant especially in the course of long-term treatments.
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n	 INTRODUCTION 
This year is the thirtieth anniversary of the published report that announced 
the discovery of what proved to be the first 
mammalian WNT gene involved in mouse 
breast cancers with the evidence of its rule 
as proto-oncogene transcriptionally acti-
vated by viruses in multiple independent 
tumors (1).
Since then it was clear that WNT genes and 
components of WNT signalling pathways 
are implicated in a wide spectrum of impor-
tant biological phenomena, ranging from 
early organ development to cell behaviour 
in several diseases, not only cancers.
The WNT signalling pathway is a com-
plex system for transferring information 
for DNA expression from the cell surface 
receptors to cytoplasm and then to the nu-
cleus.
WNTs are a large family of 19 secreted gly-
coproteins that trigger multiple signalling 
cascades that are essential for embryonic 
development and tissue regeneration (2). 
WNTs represent the driving system of the 
embryo and determine body axes and drive 
organs growing in the right direction (3). In 
addition, WNT signalling orchestrate mor-
phogenesis during embryonic development 
and this signalling pathway is critical for 
the maintenance of adult stem cell com-
partments in the bone, hematopoietic and 
gastrointestinal system. Another important 
task of WNT system is the maintenance of 
self-renewing tissues such as bone marrow, 
gut and skin. 
The WNT pathway is a rather complex sig-
nalling system. On the plasma membrane 
of mammalian cells, any combination of 
19 soluble WNT ligands and 10 WNT re-
ceptors of the Frizzled (FZ) protein family 
and several co-receptors and at least four 
classes of secreted WNT signalling modu-
lators [secreted FZ-related protein family 
(SFRP), Dickkopfs (Dkks), Rspondins and 
WIF] can be present (4). 
Aberrant WNT signalling results in devel-
oping malformation and underlies different 
human pathologies such as colorectal can-
cer, osteoporosis and neurodegenerative 
disorders (3). Proteins involved in the am-
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plification and transduction of WNT sig-
nals are often altered in cancer or lineage 
progenitor cells, leading to abnormal cell 
cycle control and/or altered cell fate deci-
sions. 
Any mutations in several WNT pathway 
components might also contribute to hu-
man skeletal dysplasia (2) (Tab. I).
n	 WNT AND BONE
The molecular links between WNT signal-
ling and bone development and remodelling 
were discovered by observing mutations 
in the WNT coreceptor low-density lipo-
protein receptor-related protein 5 (LRP5). 
These mutations are linked to alterations 
in human bone mass (5-8). The discovery 
that activating and inactivating mutations 
in a WNT co-receptor can lead both to high 
bone mass and low bone mass in human 
beings, demonstrated that WNT signalling 
is a dominant regulator of bone density in 
humans and this point was then confirmed 
also in mouse genetic studies (9). Even 
small changes in the intensity, amplitude 
and duration of WNT signalling are able to 
interfere with skeletal development as well 
as bone remodelling, regeneration and re-
pair during life. In addition, a number of 
polymorphisms in different WNT pathway 
Table I - Human diseases associated with mutations of the WNT signaling components. 
Gene altered function Type of alteration Disease
PORCN Enhancing WNT lipid modification/processing LOF X linked focal dermal hypoplasia
Wnt3 Enhancing ligands for WNT signaling LOF Tetramelia
Wnt4 Enhancing ligands for WNT signaling LOF Mullerian-duct regression and viriliation
Wnt5b Enhancing ligands for WNT signaling Unknown Type II diabetes
Wnt7a Enhancing ligands for WNT signaling LOF Fuhrmann syndrome
Wnt10a Enhancing ligands for WNT signaling LOF Odonto-onycho-dermal hypoplasia
Wnt10b Enhancing ligands for WNT signaling LOF Obesity
RSPO1 Enhancing WNT agonists LOF XX sex reversal - Hyperkeratosis
RSPO4 Enhancing WNT agonists LOF Autosomal recessive anonychia-hyponychia congenita
SOST Inhibition of LRP 5/6 antagonists LOF Sclerostosis/Van Buchem disease
Norrin (NDP) Enhancing specific ligands during eye development LOF -
LRP5 Enhancing WNT coreceptors
GOF
LOF
Hyperparathyroid tumors
High bone mass
Osteoporosis-pseudoglioma
FEVR eye vascular defects
Early coronary disease and
osteoporosis
LRP6 Enhancing WNT coreceptors LOF Early coronary disease and osteoporosis
FZD4 Enhancing WNT receptors LOF Familial exudative vitreoretinopathy
Axin 1 Inhibition of beta-catenin degradation LOF Caudal duplication, cancer
Axin 2 Inhibition of beta-catenin degradation LOF Tooth agenesis, cancer
APC Inhibition of beta-catenin degradation LOF
Familial adenomatous polyposis, 
cancer
WTX Inhibition of beta-catenin degradation LOF Wilms tumor
Beta-catenin 
(CTNNB1) Enhancing of pro oncogene action GOF Cancer
LOF, loss of function; GOF, gain of function; LRP, low-density lipoprotein receptor; FEVR, familial exudative 
vitreoretinopathy. Modified from MacDonald et al., 2009 (47).
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components have been identified and found 
to be linked to altered bone mineral density 
(10-14). So in the last few years the inter-
est for the WNT signalling pathways has 
been growing for their relevance in skeletal 
development, bone mass maintenance and 
potential therapeutic implications. 
The WNT pathways involve all bone cells: 
osteoblasts, osteocytes and osteoclasts. 
Mesenchymal stem cells (MSC) resident in 
the bone cavity give rise to most marrow 
stromal cell lineages, including chondro-
cytes, osteoblasts, fibroblasts, adipocytes, 
endothelial cells, and myocytes (15). Os-
teoblasts are responsible for bone forma-
tion. Osteocytes are terminally differenti-
ated osteoblasts embedded within the min-
eralized matrix that communicate changes 
in mechanical loading and extracellular en-
vironment to osteoblasts and osteoclasts on 
bone surface and so regulate bone remod-
eling and fracture repair (16). Osteoclasts 
originate from hematopoietic stem cells 
and are responsible for bone resorption 
(17). Several basic studies have suggested 
that WNT signalling enhances bone forma-
tion by regulating osteoblast and osteoclast 
proliferation and differentiation through 
well-characterized steps:
1) WNT signalling is crucial for the dif-
ferentiation of osteoblasts from mes-
enchymal precursors (18), by shifting 
MSC differentiation from chondrocyte 
and adipocyte to osteoblast (19-23);
2) WNT signalling is associated with pro-
liferation, maturation and survival of 
osteoblasts. A subgroup of WNT in-
duces a cascade of intracellular events 
that stabilize beta-catenin, facilitating 
its transport to nucleus where it binds 
Lef1/Tcf transcription factors and alters 
gene expression to promote osteoblast 
expansion, proliferation, function, and 
survival (24);
3) WNT signalling is also implicated in 
the coupling of osteblast and osteoclast 
activity. The enhancing osteoblast dif-
ferentiation ensues in increased syn-
thesis and secretion of osteoprotegerin 
(OPG), a competitive inhibitor of re-
ceptor activator of nuclear factor kap-
pa B (RANKL). It also interferes with 
RANK-RANKL interaction which is 
essential for osteoclast maturation and 
activity. In this way WNT, indirectly, 
can block osteoclast differentiation. 
Thus, WNT signalling may be associat-
ed with both increased bone formation 
and inhibition of osteoclast-mediated 
bone resorption (25).
n	 THE WNT PATHWAYS
WNTs trigger different signalling cas-
cades. We can distinguish two different 
pathways: canonical and non-canonical 
which are depending on the typology of 
WNT, cell surface receptors present on re-
cipient cells and on local concentration of 
WNT antagonists.
The canonical WNT-beta catenin signal-
ling
The best-known pathway is the so-called 
canonical pathway that leads to stabiliza-
tion and nuclear translocation of the beta-
catenin, normally present in the cytoplasm. 
A key component of canonical WNT 
pathway is Axin which negatively regu-
lates WNT signalling by facilitating the 
phosphorylation and degradation of beta-
catenin. In absence of WNTs, beta-catenin 
is quickly sequestered and degraded by 
ubiquitin-mediated proteolysis (2, 24). 
Binding of certain WNTs (e.g. WNT3a) 
with specific cell surface receptors leads 
to inactivation of beta-catenin proteolysis 
also through the degradation of Axin (26). 
This way beta-catenin becomes stable, its 
cytoplasmic levels are increased and it can 
enter in the nucleus where it regulates the 
expression of target genes displacing co-
repressors from transcriptional factors (2). 
The WNT canonical pathway contributes 
to differentiation, proliferation and surviv-
al of osteoblasts (24) and it regulates the 
expression of OPG inhibiting osteoclast-
mediated bone resorption (25).
WNT pathways play a key role in determin-
ing the fate of MSC. In absence of β-catenin 
these cells do not differentiate into mature 
osteocalcin-expressing osteoblasts (19, 20) 
but only into chondrocytes. On the contrary, 
No
n-c
om
me
r i
al 
us
e o
nly
review
222 Reumatismo 5/2013
S. Tamanini, L. Idolazzi, D. Gatti et al.
WNT canonical signalling prevents progen-
itor cells differentiating down the chondro-
cyte lineage and targeting them instead to 
the osteoblast lineage (21, 22). WNT signal-
ling pathways promote osteoblastogenesis 
also by suppressing adipogene sis. Inducers 
of differentiation in one lineage often inhibit 
differentiation along the others. Thus, for 
example, peroxisome proliferator activated 
receptor gamma (PPAR-gamma) is a tran-
scription factor that induces adipogenesis 
and inhibits osteoblastogenesis (27). Both 
canonical and non-canonical WNT path-
ways induce osteoblastogenesis and sup-
press adipogenesis by reducing the expres-
sion of PPAR-gamma (23, 28) (Fig. 1).
The WNT-non-canonical pathways
Sometimes WNTs do not activate the beta-
catenin canonical pathway but they rather 
trigger alternative intracellular events (non 
canonical pathways). Beta-catenin inde-
pendent signalling are mediated by several 
kinases such as mitogen-activated protein, 
protein kinase and calcium/calmodulin-
dependent protein kinase (23). These path-
ways regulate cellular proliferation, differ-
entiation, migration and polarity (2). The 
effects on bone are subjected to intensive 
investigation but it is likely that also non-
canonical WNT signalling supports normal 
bone physiology in adults. In this context 
it should be emphasized that non canoni-
cal WNT ligands and their receptors are 
expressed in adult bone at level compara-
ble to those for canonical WNT signalling 
pathways (23) but its role in supporting os-
teoblastogenesis is still poorly understood. 
A non-canonical WNT ligand (WNT5A) 
strongly suppresses transcription of PPAR-
gamma and has emerged as an MSC fate 
determinant through shifting MSC differ-
entiation from adipocyte to osteoblast (29). 
The timing of this non-canonical WNT ac-
tion seems to be critical in inducing osteo-
blastogenesis over adipogenesis (23).
Tipology of WNT
WNTs are a family of secreted glycopro-
teins. The processing and secretion of all 
WNTs are under the control of seven-pass-
transmembrane protein called WNTless 
(30-32) that is expressed ubiquitously in 
human and rodent cells (33, 34). This in-
dicates that WNTs are important for all 
cell type both during foetal and postnatal 
growth. Cells recognize WNTs through 10 
Frizzled receptors and their co-receptors 
low-density lipoprotein receptor-related 
protein: LRP5 or LRP6 and potentially 
LRP4 (2). The large number of ligands 
and receptors and of their possible com-
binations contributes to widely variable 
cellular responses depending on the mol-
ecules present. Historically, two different 
metabolic pathways (canonical and non 
canonical) were identified based on their 
ability to activate beta catenin. In gen-
eral, WNT1, WNT3a, WNT5a, WNT7a, 
WNT8a and WNT10a are considered ac-
tivators of the canonical pathway, whereas 
WNT5a or WNT11 are best known for 
their ability to trigger non-canonical WNT 
signalling (23, 35). This distinction is not 
so clear since some WNTs may activate 
both pathways depending on the cellular 
contest and the presence of appropriate 
Frizzled receptors (2, 35).
Figure 1 - The WNT pathway and cellular lines involved. It is showed 
how both the canonical and non-canonical pathways play a role in the 
maturation of osteoblasts and how the inhibition of WNT system can 
lead to a different fate for the mesenchymal stem cell.
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n	 WNT-RECEPTORS
Frizzleds
WNTs exert their biological effects by 
binding and then activating cell surface re-
ceptors, called Frizzled, that are members 
of the G protein-coupled receptors super-
family. Like the other G protein-coupled 
receptors also Frizzleds can be considered 
membrane receptors with three basic re-
gions (36):
1) the N-terminal, exofacial domains. 
These participate in binding WNT or 
other antagonists, with and without 
co-receptors like LDL receptor-related 
proteins: LRP5/6. The latter include 
members of the SFRP, of the Dkk fam-
ily ligands and sclerostin (SCL) (36). 
Activation of the canonical pathway is 
initiated when WNT associates with 
FZ and LRP5/6, while the activation 
of non-canonical pathway seems to in-
volve interaction of WNT with FZ but 
in absence of LRP5/6 (37);
2) a transmembrane central core com-
posed of seven, hydrophobic alpha-hel-
ices that span the lipid bilayers;
3) at least three intracellular loops and a 
C-terminal tail that constitute the cyto-
plasmic domains- They are intimately 
involved in signal propagation first to 
heterotrimeric G-proteins and then to 
downstream signalling elements found 
in the cellular cytoplasm (36, 38). 
Low-density lipoprotein receptor-related 
proteins
Low-density lipoprotein receptor-related 
proteins are plasma membrane receptors 
involved in lipid metabolism, transport and 
cellular signalling. The initiation of the 
WNT-beta catenin signalling cascade takes 
place when FZ form a complex together 
with WNT-ligands and with the WNT-core-
ceptors LRP5 or LRP6. These co-receptors 
exhibit a highly conserved domain struc-
ture and consist of a large extracellular do-
main, a small transmembrane region and a 
cytoplasmatic domain (39-41). LRP5 and 
6 show low affinity for WNTs and high af-
finity for soluble antagonists such as SCL 
and Dkk1 (2) which are therefore essential 
for the regulation of WNT activation and 
inhibition.
LRP5 is required for efficient WNT signal-
ling and beta-catenin activation in osteo-
blasts (2). It plays a key role in regulation 
of bone mass either through a direct control 
of osteoblast-lineage cells or indirectly in 
endocrine and paracrine manner, control-
ling bone formation by inhibiting serotonin 
synthesis in the duodenum (42). 
LRP6 share 70% amino acid identity with 
LRP5 and has many similar properties. 
This co-receptor contributes also to opti-
mal parathyroid hormone (PTH) signalling 
in osteoblasts (43). Recently it has been 
shown that LRP6 plays an essential role in 
WNT3a/beta catenin signalling and inhibi-
tion of adipogenic differentiation of stem 
cells actions that cannot be replaced by 
LRP5 (44).
LRP4 is an emerging regulator of bone 
mass. It can antagonize canonical WNT 
pathway in vitro (45) and modulates sever-
al signalling pathways in skeletal and tooth 
development especially in craniofacial or-
ganogenesis (46). 
The loss of function in LRP5 gene is in-
volved in the osteoporosis pseudoganglio-
ma syndrome, a recessive disorder charac-
terized by low bone mass and abnormal eye 
vasculature (5, 47, 48).
Conversely patients with autosomal domi-
nant high bone mass diseases harbor LRP5 
missense (gain-of-function) mutations 
(49), which are clustered in the LRP5 ex-
tracellular domain and render LRP5 resis-
tant to binding and inhibition by the antag-
onist SOST (50, 51) and DKK1 (52).
WNT-antagonists
Secreted WNT antagonists can inhibit 
WNT signalling by binding either WNTs 
or LRP5/6 co-receptors, leading in both 
cases to inhibition of the aggregation of the 
3 components of the WNT pathway.
Secreted frizzled-related proteins
Secreted frizzled-related proteins (SFRPs) 
include 5 members of secreted, cysteine-
rich glycoproteins SFRPs that directly bind 
to WNTs/FZ complex, preventing their 
functional association with FZs on the cell 
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surface (37). SFRP1 is the most extensive-
ly studied and its cysteine rich domain has 
homology with the FZ-WNT receptor (53, 
54). Study on KO animals and cell cultures 
showed that the lack of SFRP1 is associ-
ated with high trabecular bone density sim-
ilar to that seen during treatment with PTH 
(55,56) while its overexpression in mice 
is associated with decreased bone density 
and with the prevention of the anabolic ef-
fect of PTH (57). SFRP1 might be involved 
also in glucocorticoid induced osteoporosis 
since its expression is increased by dexa-
methasone (58). It was also suggested that 
SFRP1 may also bind RANKL and then 
block osteoblast-induced osteoclastogen-
esis (59). This way SFRP1 might inhibits 
both osteoblast and osteoclast activity (58). 
Dickkopfs
The Dickkopfs family comprises four 
members (Dkk1 to Dkk4) and a unique 
Dkk3 related protein named Soggy (37). 
DKK1 is the most studied member of the 
family, it is expressed and active in many 
tissue (60) and regulates bone mass in hu-
man. Dkk1 inhibits WNT-induced stabilisa-
tion of beta catenin by binding to LRP5/6. 
Dkk1 also interacts with another class of 
receptors (Kremen 1 and 2) to form a ter-
nary complex (Kremen-Dkk1-LRP6) that 
blocks WNT-LRP6 signalling by inducing 
endocytosis and removal of WNT recep-
tor from the plasma membrane (61). The 
internalisation of LRP5/6 with Kremen re-
ceptors seems to inhibit the degradation of 
Axin. Then it promotes the degradation of 
beta-catenin in order to inhibit the canoni-
cal WNT pathway (37). The antagonistic 
effect of Dkk1, mediated by LRP5/6, might 
be specific to the WNT beta-catenin path-
way since the activation of non-canonical 
WNT pathway is not affected (62).
Dkk1 counteracts the WNT-beta-catenin 
effects on bone differentiation by promot-
ing adipogenesis (60). WNT Beta-catenin 
pathway activation not only stimulates new 
bone formation but it also inhibits osteo-
clastogenesis by increasing OPG, the de-
coy protein for RANKL (25). In addition 
to bone formation impairment, Dkk1 over-
expression shifts the OPG:RANKL ratio to 
favour bone resorption. At variance with 
SFRP which blunts both bone formation 
and bone resorption, Dkk1 inhibits bone 
formation and favours osteoclastic bone 
resorption.
The role played by other DKKs is less 
clear. The activity of Dkk3 and 4 appear 
similar to the Dkk1 one, but is apparently 
not expressed by bone cells (2). The mo-
lecular functions of Dkk2 are more compli-
cated and vary with cellular context. Both 
Dkk1 and Dkk2 can bind to LRP6 (61) but 
Dkk2 can either antagonise either stimulate 
(37) WNT beta-catenin pathway. These op-
posing effects may be modulated by Kre-
mer 2 which converts Dkk2 from agonist 
to antagonist of LRP6 (63). Moreover in 
the presence of high WNT7b levels DKK2 
induce terminal osteoblast differentiation 
(64).
Sclerostin
Bone remodeling is the physiological pro-
cess by which bone tissue is continually 
removed and replaced on the surface of 
trabecular bone and within the Haversian 
systems of cortical bone. 
This process requires the activity of three 
different types of cells - osteoclasts (bone 
resorbing cells), osteoblasts (bone form-
ing cells), and osteocytes. Osteocytes are 
former osteoblasts that were trapped in 
the newly formed bone matrix. They com-
municate with one another and with bone 
lining cells of bone surface through a net-
work of cytoplasmic connections (65) and 
are cells that detect loads applied to bone. 
Over loading is associated with local stim-
ulation of bone formation and vice-versa. 
This mechanoregulatory mechanism is me-
diated by SCL expressed almost uniquely 
by osteocytes. 
Sclerostin is a monomeric glycoprotein that 
antagonizes WNT/beta-catenin signalling 
(66) in osteoblasts as DKK1, by binding to 
LRP5 and LRP6 and preventing their asso-
ciation with FZ and WNTs. This results in 
the inhibition of osteoblast differentiation, 
activity, and survival (67).
SCL is the product of the SOST gene, which 
is mutated and down-regulated in patients 
with sclerosteosis and van Buchem’s dis-
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ease (68, 69) two rare bone sclerosing dis-
orders characterized by endosteal hyper-
ostosis, progressive generalized osteoscle-
rosis, and high bone mass associated with 
increased osteoblastic activity and elevated 
bone formation markers (70). 
As it often happens, identification of the 
genetic and molecular origin of a rare dis-
ease has revealed an important mechanism 
in normal physiological processes with po-
tential implication for the development of 
new treatments for common diseases. The 
concept that osteocytes have a mechano-
sensing role with sclerostin as a key signal-
ling protein for osteoblasts is supported by 
several preclinical studies (71). Bone load-
ing in animals is associated with decreased 
expression of SCL by osteocytes and with 
an increase in bone formation while bone 
unloading is associated with an increase 
in SOST transcription (72), up-regulation 
of sclerostin, and a decrease in WNT/beta-
catenin signalling (73). 
Bone density and mechanical strength are 
elevated in Sost knockout mice (74, 75) 
whereas transgenic overexpression of Sost 
induces osteopenia (76, 77).
All these data suggest that disuse osteopo-
rosis may in part be mediated by scleros-
tin-related inhibition of osteoblastic bone 
formation and that SCL is an important 
negative regulator of bone formation. 
Evidence points out that in addition to its 
anti-anabolic role, sclerostin has a cata-
bolic activity. Sclerostin dose-dependently 
up-regulates the expression of RANKL 
mRNA and down-regulates the expression 
of OPG mRNA, causing an increase in the 
RANK:OPG mRNA ratio (78), enhancing 
osteoclast activity. This action seems simi-
lar to DKK1 and is due to the inhibition 
of WNT canonical pathway in which beta-
catenin induces an increase in synthesis 
and secretion of OPG (25).
SCL seems also to be an important media-
tor of the anabolic effect of PTH in bone. 
PTH suppresses SCL expression both in vi-
tro and in vivo (79, 80) while over-expres-
sion of SOST prevent in rats the anabolic 
response to PTH administration (81, 82).
Unlike DKKs and SFRP, SCL is produced 
primarily by bone cells and is abundant es-
pecially in the osteocytic canalicular sys-
tem (83, 84) SCL has also been detected in 
cementocytes in teeth, mineralized hyper-
trophic chondrocytes in the growth plate, 
and osteoarthritic cartilage (85, 86). SCL 
may also be expressed by osteoclast pre-
cursors but not in by mature osteoclasts 
(87).
The WNT pathway with their several com-
ponents seem to have a key role in bone 
development, remodeling, and repair al-
though there is still much to understand 
and to study and much remains to be dis-
covered. However already now our knowl-
edge allows us to recognize this pathway as 
a possible source of new therapeutic strate-
gies for common disease characterized by 
altered bone mass as osteoporosis, of high 
socioeconomic burden (88). Some of these 
treatments are already in advanced stage of 
development (89).
Moreover this pathway is probably involved 
in the metabolic response to treatment with 
bone active agents used for the treatment 
of post-menopausal and male osteoporosis 
(90). In fact some of their effects on bone 
turnover are related with changes in the 
WNT/beta-catenin signalling. For example 
treatment with estrogens or raloxifene, but 
Figure 2 - The increase in serum sclerostin during treatment with ner-
idronate versus placebo. The association between neridronate treat-
ment and increased sclerostin levels suggests that the inhibition of 
bone formation observed after extended treatment with bisphospho-
nates might be mediated, at least in part, by an increase in sclerostin 
(modified from Gatti et al., 2011 (94)).
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not with androgens, is associated with a de-
crease in SCL levels (91, 92).
For this reason we decided to study both 
the changes in the WNT-antagonists serum 
levels (SCL and DKK1) during antiresorp-
tive (bisphosphonates and denosumab) and 
anabolic treatment (teriparatide) (93). 
Bisphosphonates are known to directly 
suppress osteoclastic activity, but the sup-
pression of bone resorption is typically as-
sociated with a later decrease of bone for-
mation. 
To determine whether this decrease in bone 
formation is associated with changes in se-
rum levels of SCL or DKK1, 107 patients 
were treated with either monthly intramus-
cular neridronate or placebo (88). Serum 
C-terminal telopeptide of type I collagen 
(sCTX, a bone-resorption marker) and bone 
alkaline phosphatase (bAP, a bone-forma-
tion marker) decreased, as expected, during 
neridronate treatment. Serum DKK1 re-
mained unchanged at all time points while 
serum SCL increased versus placebo group 
gradually and significantly only in patients 
treated with two upper doses (25 or 50 mg 
neridronate monthly), reaching 138-148% 
of baseline values (P<0.001) (Fig. 2). In 
consideration of the anti-anabolic effects 
of sclerostin on bone formation, the asso-
ciation between neridronate treatment and 
increased sclerostin levels suggests that the 
inhibition of bone formation observed after 
extended treatment with bisphosphonates 
might be mediated, at least in part, by an 
increase in sclerostin. Indeed we found a 
negative correlation (P<0.001) between the 
changes in bAP and sclerostin but causal 
link remains hypothetical (94).
This effect of bisphosphonates on WNT-
antagonist appears to be different from 
that we found in patients treated with de-
nosumab (95), an antiresorptive drug that, 
suppressing RANKL activity, lowers the 
number not only of actively resorbing os-
teoclasts (as bisphosphonates do) but also 
of osteoclast precursors. In our study deno-
sumab therapy was found to be associated 
with increasing SCL levels (as bisphospho-
nates treatment) but it was also associated 
with declining serum levels of DKK1 (95) 
and this might explain the apparent per-
sistent slight positive unbalance between 
suppressed bone resorption and formation 
during denosumab treatment (96).
The WNT-pathway is also involved in the 
response to bone anabolic agents. It has 
been reported that treatment with analogs 
of PTH or teriparatide is associated with 
decreases in serum SCL (97-99). These 
observations strongly suggest that the posi-
tive effect of PTH on osteoblast activity 
is at least in part mediated by changes in 
the WNT/β catenin signalling. It was also 
found that the effect of teriparatide on 
SOST disappears within a few months and 
that long-term treatment is associated with 
an increase in DKK1 (100). This might ex-
plains the loss of the bone anabolic effect 
of teriparatide after 18-24 months of con-
tinuous treatment. 
In conclusion the WNT-pathway and in 
particular its antagonists SCL and DKK1 
seems to play a key role in the regulation 
of bone remodeling in a number of clinical 
conditions and during treatment with bone 
active agents, such as bisphosphonates, 
but not only. Their effects become relevant 
especially in the course of long-term treat-
ments.
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